Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyposis
John V Boyle, Kent Lam, Joseph K. Han
Abstract
, have shown that dupilumab improves both subjective patient-reported outcomes and objective physician-evaluated metrics for CRSwNP. The favorable findings have resulted in approval by the US FDA in June 2019 as the first biologic therapy for CRSwNP.
Topics & Concepts
DupilumabMedicineChronic rhinosinusitisNasal polypsDiseaseMonoclonal antibodyImmunologySinusitisQuality of life (healthcare)Clinical trialPathophysiologyInternal medicineAsthmaAntibodyNursingSinusitis and nasal conditionsAsthma and respiratory diseasesAllergic Rhinitis and Sensitization